Core Viewpoint - The company, Rundu Co., has received a drug registration certificate from the National Medical Products Administration for its product, Valsartan Amlodipine Tablets (I) [2] Company Summary - Rundu Co. announced the receipt of the drug registration certificate on the evening of September 29 [2] - The registered drug is Valsartan Amlodipine Tablets (I), indicating a new product introduction in the pharmaceutical market [2] Industry Summary - The approval of Valsartan Amlodipine Tablets (I) reflects ongoing regulatory support for new drug registrations in the pharmaceutical industry [2] - This development may enhance the competitive landscape within the cardiovascular drug segment [2]

Group 1 - Yinglian Co., Ltd. expects a net profit increase of 1531.13% to 1672.97% year-on-year for the first three quarters of 2025, with projected revenue of 1.63 billion to 1.65 billion yuan, a growth of 9.49% to 10.83% [1] - Meixin Sheng plans to reduce its shareholding by no more than 1% through centralized bidding and block trading [1] - Huayin Technology signed two sales contracts totaling 402 million yuan, with one contract for special functional materials and another for research project materials [3] Group 2 - Shen Highways reported a total toll revenue of 114 million yuan for August [5] - Dash Smart signed a contract worth 113 million yuan for a smart hospital project [7] - Tianbang Food received an administrative regulatory measure decision from the China Securities Regulatory Commission for failing to disclose information in a timely manner [8] Group 3 - Fashilong plans to invest 250 million yuan to establish a wholly-owned subsidiary focused on AI applications and cloud computing [10] - Junpu Intelligent received a government subsidy of 20 million yuan, accounting for 243.97% of its audited net profit for 2024 [11] - Longyun Co. plans to apply for a bank credit limit of 32 million yuan [12] Group 4 - Yifan Pharmaceutical's subsidiary received acceptance for a drug registration application for a medication used to lower phenylalanine levels in patients [12] - Rundu Co. received a drug registration certificate for a hypertension medication [13] - Huahai Qingke elected a new employee director and appointed a new vice president [17] Group 5 - Wanyi Technology received a government subsidy of 173,000 yuan [19] - Haizheng Pharmaceutical's tacrolimus capsules passed the consistency evaluation for generic drugs [20] - Pulaike's new veterinary vaccine received registration certification [22] Group 6 - Boguang New Materials signed a major sales contract estimated at 4.3 billion to 5 billion yuan for nickel powder products [41] - Electric Soul Network announced plans for shareholders to reduce their holdings by up to 1.63% [42] - Jin Haitong's shareholders plan to reduce their holdings by up to 3% [44]

润都股份（002923）(002923.SZ)发布公告，公司近日收到国家药品监督管理局签发的《药品注册证 书》，涉及药品：缬沙坦氨氯地平片(I)。本品适用于治疗原发性高血压。本品用于单药治疗不能充分控 制血压的患者。 ...

智通财经APP讯，润都股份(002923.SZ)发布公告，公司近日收到国家药品监督管理局签发的《药品注册 证书》，涉及药品：缬沙坦氨氯地平片(I)。本品适用于治疗原发性高血压。本品用于单药治疗不能充分 控制血压的患者。 ...

Group 1 - The core point of the article is that Rundu Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for its product "Valsartan Amlodipine Tablets (I)" [1] - As of the first half of 2025, the revenue composition of Rundu Co., Ltd. is as follows: 56.18% from chemical drug formulation manufacturing, 42.61% from active pharmaceutical ingredient manufacturing, and 1.2% from other businesses [1] - The current market capitalization of Rundu Co., Ltd. is 4.2 billion yuan [1] Group 2 - The article mentions a competitive scenario where Nongfu Spring's green bottle launch has negatively impacted the market share of Yibao, which has dropped nearly 5 percentage points [1]

证券代码：002923 证券简称：润都股份 公告编号：2025-045 珠海润都制药股份有限公司 关于缬沙坦氨氯地平片（I）获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 珠海润都制药股份有限公司（以下简称"公司"或"本公司"）近日收到国 家药品监督管理局签发的《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药品名称：缬沙坦氨氯地平片（I）（以下简称"本品"） 剂型：片剂 申请事项：药品注册（境内生产） 规格：每片含缬沙坦80mg，苯磺酸氨氯地平5mg（按C₂₀H₂₅ClN₂O₅计） 注册分类：化学药品 4 类 受理号：CYHS2400118 证书编号：2025S02990 药品批准文号：国药准字 H20255570 药品注册标准编号：YBH24072025 本品未来市场销售情况可能受到行业政策变动、招标采购、市场环境变化等 因素影响，存在不确定性，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 珠海润都制药股份有限公司 董事会 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要 ...

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for Valsartan Amlodipine Tablets, which will enhance its product offerings in the antihypertensive market [1] Group 1: Drug Registration Details - The drug is named Valsartan Amlodipine Tablets (I) and is in tablet form, with each tablet containing 80mg of Valsartan and 5mg of Amlodipine [1] - The approval number for the drug is Guo Yao Zhun Zi H20255570, classified as a Class 4 chemical drug [1] Group 2: Indication and Market Impact - The drug is indicated for the treatment of primary hypertension, specifically for patients whose blood pressure cannot be adequately controlled with monotherapy [1] - The acquisition of this drug registration certificate will further enrich the company's antihypertensive product line and enhance its market competitiveness in the hypertension sector [1]

珠海润都制药股份有限公司 关于盐酸伐昔洛韦片获得药品补充申请批准通知书的公告 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 ■ 珠海润都制药股份有限公司（以下简称"公司"或"本公司"）近日收到国家药品监督管理局签发的《药品 补充申请批准通知书》。现将有关情况公告如下： 一、药品基本情况 药品名称：盐酸伐昔洛韦片（以下简称"本品"） 剂型：片剂 药品注册标准编号：YBH25122025 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医疗器械审评审批制度的意 见》（国发〔2015〕44号）和《关于仿制药质量和疗效一致性评价工作有关事项的公告》（2017年第 100号）的规定，经审查，本品通过仿制药质量和疗效一致性评价。同意增加规格0.5g（按C??H??N?O? 计），发给药品批准文号。 二、药品的适应症 申请内容：仿制药质量和疗效一致性评价 规格：0.5g（按C??H??N?O?计） 包装规格：30片/瓶 注册分类：化学药品 受理号：CYHB2450554 通知书编号：2025B04393 药 ...

（文章来源：证券日报） 证券日报网讯 9月25日晚间，润都股份发布公告称，公司近日收到国家药品监督管理局签发的《药品补 充申请批准通知书》。药品名称：盐酸伐昔洛韦片。 ...

Group 1: Investment and Fundraising - Hanyu Pharmaceutical plans to raise no more than 968 million yuan for the development of semaglutide and other projects [1] - Ganfeng Lithium intends to introduce investors for a capital increase of up to 2.5 billion yuan [9] Group 2: Strategic Restructuring - Pingmei Shenma Holdings is undergoing a strategic restructuring as directed by the Henan provincial government, which will not affect the company's operations significantly [2][8] - Shennong Holdings is also involved in a strategic restructuring with no change in control or significant impact on operations [7][8] Group 3: Clinical Trials and Approvals - XinNuoWei's subsidiary received approval for clinical trials of a drug for treating mild Alzheimer's disease, marking a significant milestone in the development of biosimilar drugs [3] - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for rosacea, a first-class innovative drug in China [4] - Baili Tianheng's drug, iza-bren, has been included in the list of breakthrough therapies, indicating its potential in treating advanced urinary tract cancer [5] Group 4: Contracts and Projects - Zhongyou Engineering signed an EPC contract worth 2.524 billion USD for a seawater pipeline project in Iraq, expected to positively impact future revenues [6]